Company Profile
Avinger Stock Price, News & Analysis
- Ticker:
- AVGR
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for AVGR.
Company overview
Business overview
Avinger is a medical device company focused on image-guided vascular intervention systems. Its business is centered on procedure-linked devices used to treat peripheral artery disease and related vascular conditions.
Geographic Base and Sector Classification
Avinger is headquartered in the United States and listed on NASDAQ. It sits in vascular medtech rather than biotechnology.
Business Model Characteristics
The company depends on device adoption, hospital or physician training, and the ability to scale procedure-based sales. Investors watch product clearance, commercialization, and operating execution.
Position Within the Biotechnology Landscape
Avinger belongs in the vascular-device layer of healthcare. It is not biotech, but its stock is driven by procedural adoption and product execution.
Future catalysts
Avinger’s catalysts are image-guided atherectomy adoption and any commercialization update that shows the device can keep finding a durable clinical niche. The company needs recurring procedural use to matter.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Avinger do?
Avinger is a medical device company focused on image-guided vascular intervention systems. Its business is centered on procedure-linked devices used to treat peripheral artery disease and related vascular conditions.
On which exchange is AVGR stock listed?
Avinger (AVGR) is associated with NASDAQ, United States, MedTech.
What is Avinger?
Avinger’s catalysts are image-guided atherectomy adoption and any commercialization update that shows the device can keep finding a durable clinical niche.
Which conditions is Avinger targeting with Avinger?
Avinger’s catalysts are image-guided atherectomy adoption and any commercialization update that shows the device can keep finding a durable clinical niche.
How does Avinger describe recent progress with Avinger?
Avinger’s catalysts are image-guided atherectomy adoption and any commercialization update that shows the device can keep finding a durable clinical niche.
What future catalysts are investors watching for Avinger?
Avinger’s catalysts are image-guided atherectomy adoption and any commercialization update that shows the device can keep finding a durable clinical niche. The company needs recurring procedural use to matter.